Clinical Trials Logo
  1. Home
  2. Atrial Fibrillation (AF)
  3. NCT05712200

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) — LILAC-TIMI 76  

Atrial Fibrillation (AF) Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Clinical Trial Summary

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05712200
Study type Interventional
Source Anthos Therapeutics, Inc.
Contact Anthos Therapeutics
Phone +1 617 430 6940
Email clinicaltrials@anthostherapeutics.com
Status Recruiting
Phase Phase 3
Start date December 27, 2022
Completion date March 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02630914 - Medical and Surgical Hybrid Treatment of Atrial Fibrillation. N/A
Completed NCT05410379 - Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
Enrolling by invitation NCT05407415 - KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation N/A
Completed NCT04025710 - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep) N/A
Completed NCT01119274 - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Phase 4
Recruiting NCT03428048 - Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
Recruiting NCT04298723 - Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding. N/A
Completed NCT04218266 - Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. Phase 2
Active, not recruiting NCT03732794 - AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment N/A
Active, not recruiting NCT04755283 - Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Phase 2
Completed NCT04095559 - Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
Recruiting NCT05955365 - Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation Phase 4
Recruiting NCT05294445 - From the Emergency Department Directly to Ablation of Atrial Fibrillation Study N/A
Completed NCT02513316 - Clinical Relevance of Microbleeds In Stroke N/A
Completed NCT04809922 - Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation